Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BMS-986299

Generic Name: BMS-986299

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Phase 1

Terminated

Posted: 2018/02/23

Sponsor:Bristol-Myers Squibb

ID:NCT03444753

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

MD Anderson Reports Breakthrough in Metastatic Prostate Cancer Treatment with Targeted Therapy

3 months ago

New research from MD Anderson's X-Met consortium demonstrates metastasis-directed therapy improves survival rates to 92% at three years compared to 86% with standard care in oligometastatic prostate cancer patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy